Dengue in Brazil in 2017: what happened?

test

Arbovirus control: what is the (real) stone in the way?

b

Perspectives on the Zika outbreak: herd immunity, antibody-dependent enhancement and vaccine

Submitted by Adagilson Silva ([email protected]) on 2017-05-05T18:22:21Z No. of bitstreams: 1 zika17abr25.pdf: 150751 bytes, checksum: 7c2ffa760d310a51900bc0b7bc387677 (MD5)Approved for entry into archive by Adagilson Silva ([email protected]) on 2017-05-05T18:26:57Z (GMT) No. of bitstreams: 1 zika17abr25.pdf: 150751 bytes, checksum: 7c2ffa760d310a51900bc0b7bc387677 (MD5)Made available in DSpace on 2017-05-05T18:26:57Z (GMT). No. of bitstreams: 1 zika17abr25.pdf: 150751 bytes, checksum: 7c2ffa760d310a51900bc0b7bc387677 (MD5) Previous issue date: 2017Fundação Oswaldo Cruz. Centro de Pesquisas Aggeu Magalhães. Departamento de Virologia e Terapia Experimental. Recife, PE, Brazil.Universidade Federal de Pernambuco. Laboratório de Imunopatologia Keizo Asami. Setor de Virologia. Recife, PE, Brazil.Fundação Oswaldo Cruz. Centro de Pesquisas Aggeu Magalhães. Departamento de Virologia e Terapia Experimental. Recife, PE, Brazil.Fundação Oswaldo Cruz. Centro de Pesquisas Aggeu Magalhães. Departamento de Virologia e Terapia Experimental. Recife, PE, Brazil.Fundação Oswaldo Cruz. Centro de Pesquisas Aggeu Magalhães. Departamento de Virologia e Terapia Experimental. Recife, PE, Brazil

Dengue in Brazil in 2017: what happened?

test

Arbovirus control: what is the (real) stone in the way?

b

Development and characterization of a packaging cell line for pseudo-infectious yellow fever virus particle generation

Introduction: Pseudo-infectious yellow fever viral particles (YFV-PIVs) have been used to study vaccines and viral packaging. Here, we report the development of a packaging cell line, which expresses the YFV prM/E proteins. Methods: HEK293 cells were transfected with YFV prM/E and C (84 nt) genes to generate HEK293-YFV-PrM/E-opt. The cells were evaluated for their ability to express the heterologous proteins and to package the replicon repYFV-17D-LucIRES, generating YFV-PIVs. Results: The expression of prM/E proteins was confirmed, and the cell line trans-packaged the replicon for recovery of a reporter for the YFV-PIVs. Conclusions: HEK293-YFV-prM/E-opt trans-packaging capacity demonstrates its possible biotechnology application

Development and characterization of a packaging cell line for pseudo-infectious yellow fever virus particle generation

Abstract INTRODUCTION: Pseudo-infectious yellow fever viral particles (YFV-PIVs) have been used to study vaccines and viral packaging. Here, we report the development of a packaging cell line, which expresses the YFV prM/E proteins. METHODS: HEK293 cells were transfected with YFV prM/E and C (84 nt) genes to generate HEK293-YFV-PrM/E-opt. The cells were evaluated for their ability to express the heterologous proteins and to package the replicon repYFV-17D-LucIRES, generating YFV-PIVs. RESULTS: The expression of prM/E proteins was confirmed, and the cell line trans-packaged the replicon for recovery of a reporter for the YFV-PIVs. CONCLUSIONS: HEK293-YFV-prM/E-opt trans-packaging capacity demonstrates its possible biotechnology application